Market Cap
$2.0B
URGN
UroGen Pharma Ltd.
$41.17 ▲ +1.54%
Prev close $40.55Market cap$2.0B
ConsensusStrong Buy
12-mo target$60.00 (+45.7%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on URGN right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (86%)
Insider Activity
$0.00 buy / $4.4M sell
Insider Net $
-$4.4M
SEC Reports
7
Press Releases
2
Price chart 30d -7.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 9, 2026 SEC Aug 5, 2026 SEC Mar 2, 2026 Press
Two UroGen Pharma insiders — the Chief Medical Officer and General Counsel — sold a combined $102K in open-market shares
CLUSTER — Impact 2/10
Sep 8, 2026 Insider
Smith Jason Drew sold 1,519 shares
General Counsel @ $42.54 ($64.6K)
Sep 8, 2026 Insider
Schoenberg Mark sold 871 shares
Chief Medical Officer @ $42.92 ($37.4K)
Sep 7, 2026 Insider
Smith Jason Drew acquired via exercise 3,334 shares
General Counsel
Sep 4, 2026 other
Aug 20, 2026 SEC UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech com
UroGen Pharma entered into an Option and Research License Agreement with IntraGel Therapeutics, securing an exclusive op
8-K — Impact 4/10
UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4M in revenue (73% Qo
8-K — Impact 7/10
UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the
Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 6, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 5, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Jul 21, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 16, 2026 | Oppenheimer | MAINTAIN | Outperformer | 52% |
| Jun 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 7, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Aug 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jul 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jun 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Price targets
Where 8 covering analysts think URGN trades over the next 12 months.
$60.00 +45.7% upside Strong Buy
Current$41.18 Low$48.00 Median$59.00 High$75.00 8 analysts
$48.00$75.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 4 neutral · avg impact 5.0/10.Plus 2 press releases.
NEUTRALCLUSTER2/10
Two UroGen Pharma insiders — the Chief Medical Officer and General Counsel — sold a combined $102K i
Sep 9, 2026
NEUTRAL8-K4/10
UroGen Pharma entered into an Option and Research License Agreement with IntraGel Therapeutics, secu
Aug 20, 2026
BULLISH8-K7/10
UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4
Aug 5, 2026
NEUTRAL8-K3/10
UroGen Pharma held its 2026 annual meeting of shareholders on June 22, 2026. Shareholders approved e
Jun 24, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 4, 2026
other
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing i
Aug 31, 2026
short_interest_report
Short Interest: URGN up 22% to 6.2M shares
Settlement 2026-08-31 | Days to cover: 6.79 | ≈12.78% of shares outstanding (est.)
Aug 20, 2026
contract
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
UroGen Enters Collaboration with IntraGel Therapeutics to expand uro-oncology and specialty cancer pipeline
Aug 17, 2026
short_volume
Short Volume: URGN — 66.3% short (0.4M / 0.6M)
Short: 397,480 | Exempt: 0 | TRF Vol: 599,858 | Short Ratio: 66.3% | Off-exchange volume (dark pool + OTC)
Aug 12, 2026
short_volume
Short Volume: URGN — 88.3% short (0.7M / 0.8M)
Short: 736,885 | Exempt: 0 | TRF Vol: 834,808 | Short Ratio: 88.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.09 | $-0.07–$0.19 | 113.3% | +287.5% | 5↑ 0↓ | $0.1B | 7 |
| Next Q | $0.39 | $-0.01–$0.77 | 173.6% | +305.2% | 5↑ 0↓ | $0.1B | 7 |
| Current FY | $-0.24 | $-0.83–$0.20 | 92.4% | +65.6% | 5↑ 0↓ | $0.3B | 7 |
| Next FY | $2.79 | $1.05–$6.64 | 1250.6% | +87.1% | 5↑ 0↓ | $0.5B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.091 | — |
| 7d ago | $0.091 | — |
| 30d ago | $-0.049 | +0.140 |
| 60d ago | $-0.113 | +0.204 |
| 90d ago | $-0.104 | +0.196 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 38 transactions. Net -$4.4M — $0.00 bought, $4.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Smith Jason Drew | General Counsel | SELL | 1,519 | $42.54 | $64.6K |
| Sep 8, 2026 | Schoenberg Mark | Chief Medical Officer | SELL | 871 | $42.92 | $37.4K |
| Sep 7, 2026 | Smith Jason Drew | General Counsel | EXERCISE | 3,334 | — | — |
| Sep 7, 2026 | Schoenberg Mark | Chief Medical Officer | EXERCISE | 1,667 | — | — |
| Aug 26, 2026 | Robinson James A. Jr. | Director | EXERCISE | 2,000 | — | — |
| Aug 20, 2026 | Schoenberg Mark | Chief Medical Officer | SELL | 60,677 | $47.05 | $2.9M |
| Jul 9, 2026 | Schoenberg Mark | Chief Medical Officer | SELL | 10,000 | $40.00 | $400.0K |
| Jun 22, 2026 | Belldegrun Arie | Director | AWARD | 20,000 | — | — |
| Jun 22, 2026 | WEN LEANA | Director | AWARD | 10,000 | — | — |
| Jun 22, 2026 | WEN LEANA | Director | AWARD | 8,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for URGN.
Shares short
6,247,498
Settlement Sep 15, 2026
Change vs prior
+0.0%
Semi-monthly cycle
Days to cover
9.2
At avg daily volume
Of shares outstanding
≈12.8%
Estimate — not % of float
All URGN filing & press-release reports (9)
- CLUSTER reportSep 9, 2026
- 8-K reportAug 20, 2026
- 8-K reportAug 5, 2026
- 8-K reportJun 24, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportMar 2, 2026
- PRESS-RELEASE reportMar 2, 2026